Loading clinical trials...
Loading clinical trials...
The Impact of Udenafil on Exercise Capacity in Severe COPD Patients
Pulmonary hypertension (PH) is a serious complication of COPD which is associated with shorter survival, more frequent exacerbation, and increased use of health resources. There is no effective pharmacological treatment for COPD-associated PH. Therefore, the investigators wanted to evaluate the effect of udenafil, a phosphodiesterase- 5 (PDE-5) inhibitor, on exercise capacity of severe COPD patients.
Study design * prospective, single arm, open-label study * Udenafil 50mg qd po for 8 weeks
Age
20 - 80 years
Sex
ALL
Healthy Volunteers
No
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Start Date
March 1, 2010
Primary Completion Date
March 1, 2011
Completion Date
May 1, 2011
Last Updated
June 20, 2011
23
ACTUAL participants
Udenafil
DRUG
Lead Sponsor
Seoul National University Hospital
Collaborators
NCT07073820
NCT07477600
NCT06899815
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions